The Evolution of Dezawa MuseCells®: What We’ve Learned Since Their Discovery

Home » Resources » Stem Cells » The Evolution of Dezawa MuseCells®: What We’ve Learned Since Their Discovery
Table of Contents
Table of Contents

Summary: Since Professor Mari Dezawa first identified Muse cells at Tohoku University in 2010, scientific understanding of this naturally occurring stem cell subpopulation has grown substantially. This guide traces key milestones, from early laboratory characterization to today’s expanding manufacturing and clinical research landscape, and explains what these milestones mean for the current understanding of Muse cell biology.

2010: The Original Discovery

Muse cells, short for multilineage-differentiating stress-enduring cells, were first identified and described by Professor Mari Dezawa’s research team in 2010. The discovery emerged from observations that a small, distinct subpopulation of cells within standard mesenchymal stem cell samples behaved differently under stress conditions, surviving and retaining differentiation potential in environments that would typically damage or destroy conventional cells. This initial characterization laid the foundation for everything that followed.

Establishing the Biological Markers

Early research focused on precisely identifying Muse cells within larger cell populations. Scientists established that these cells could be reliably identified using the marker SSEA-3 in combination with CD105, for cells isolated from bone marrow, or CD45, for cells isolated from peripheral blood. This marker-based identification system became essential for manufacturing consistency, allowing researchers and, later, manufacturers to confirm they were working with authentic Muse cell populations rather than the broader, more heterogeneous mesenchymal stem cell mixture from which they are derived.

Documenting Non-Tumorigenic Pluripotency

A pivotal area of research involved testing whether Muse cells, despite their pluripotent capacity to differentiate into cell types from all three embryonic germ layers, carried the tumor-forming risk associated with other pluripotent stem cells. Published studies documented no teratoma formation for extended periods following transplantation in laboratory models, a finding that distinguished Muse cells from embryonic stem cells and helped position them as a subject of serious ongoing research rather than a passing scientific curiosity.

Understanding Tissue Homing

As research progressed, scientists identified a specific mechanism explaining how Muse cells migrate toward damaged tissue: the S1P-S1PR2 signaling pathway. This discovery helped explain earlier observations that Muse cells, when introduced into the body, appeared to concentrate at injury sites without external direction. Understanding this tissue homing mechanism has since become central to how researchers design studies investigating potential applications across neurologic, cardiovascular, and orthopedic conditions.

From Laboratory Finding to Manufacturing Standard

As scientific understanding matured, attention shifted toward translating laboratory findings into reproducible manufacturing processes. This is where MUSE Cell Innovations emerged as the licensed global technology holder for the Dezawa protocol, establishing GMP (Good Manufacturing Practice) standards for perinatal, umbilical cord tissue-derived cell production. This transition, from academic discovery to standardized manufacturing, represents one of the most consequential developments in the field’s evolution, since it made consistent, large-scale research possible for the first time.

Where Research Stands Today

Current research includes evaluation of clinical-grade products such as CL2020, alongside continued investigation into conditions including stroke, myocardial infarction, and acute respiratory distress syndrome (ARDS). Each of these research threads builds directly on the foundational work establishing Muse cell identification, safety profile, and homing behavior. Understanding this evolution, from initial discovery to today’s expanding evidence base, helps physicians and patients place any individual claim about Dezawa MuseCells® within the broader, still-developing scientific context.

Frequently Asked Questions

When were Muse cells discovered?

Muse cells were first identified by Professor Mari Dezawa and her research team at Tohoku University in 2010.

How are Muse cells identified in the laboratory?

They are identified using the marker SSEA-3 combined with either CD105 (bone marrow-derived) or CD45 (peripheral blood-derived).

Why is non-tumorigenic pluripotency such an important finding?

It distinguishes Muse cells from other pluripotent stem cells, such as embryonic stem cells, which carry a higher risk of tumor formation. This finding has supported continued research interest in Muse cell applications.

What is tissue homing, and when was it discovered?

Tissue homing refers to the ability of Muse cells to migrate toward damaged tissue via the S1P-S1PR2 signaling pathway, a mechanism identified through research following the cells’ initial discovery.

How did manufacturing standards develop for this field?

MUSE Cell Innovations became the licensed global technology holder for the Dezawa protocol, establishing GMP manufacturing standards that translated laboratory findings into a reproducible, research-ready product.

Online booking in this window needs cookies to be turned on. You can also use our scheduling page directly: Schedule Free Call.